

VHL2 (Y12M) Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0485

DESCRIPTION	
Product Name	VHL2 (Y12M) Circular RNA for Cancer Vaccine Research
Gene Name	VHL2 (Y12M)
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	VHL2 (Y12M) Peptide
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	VHL2 (Y12M)
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	VHL2 (Y12M) Peptide
Background	Description: A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCIT_C2824).



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com

Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683
